Immunic Inc is a biopharmaceutical company focused on developing innovative treatments for autoimmune and inflammatory diseases
The company is dedicated to advancing therapies that can address unmet medical needs, utilizing a proprietary drug development platform. Immunic is particularly engaged in researching and formulating oral medications that target specific pathways in immune response, with the aim of improving the quality of life for patients suffering from conditions such as multiple sclerosis, ulcerative colitis, and other chronic inflammatory disorders. Through its commitment to scientific excellence and clinical research, Immunic seeks to establish itself as a leader in the field of immunology.
NEW YORK, NY / ACCESSWIRE / November 11, 2024 / Immunic, Inc. (NASDAQIMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced that Daniel Vitt, Ph.D., Chief Executive Officer, will present a company overview at the Q4 Investor Summit. The company will be available for 1-on-1 meetings throughout the day in addition to its presentation.
Immunic Inc (NASDAQIMUX) chief medical officer Dr Andreas Muehler discusses the importance of clinical trials in the biotech industry to mark Clinical Trials Day on May 20.
Immunic Inc (NASDAQIMUX) chief medical officer Dr Andreas Muehler discusses Inflammatory Bowel Disease (IBD) with Proactive's Stephen Gunnion to mark World IBD Day on May 19.
Immunic Inc (NASDAQIMUX) chief scientific officer Hella Kohlhof joined Proactive's Stephen Gunnion on International Celiac Day, in the middle of Celiac Disease Awareness Month, to discuss the disease and the company’s developments in treating it.
Immunic Inc (NASDAQIMUX) CEO Dr Daniel Vitt takes Proactive's Stephen Gunnion through the company's first-quarter achievements and upcoming milestones for its clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases.
Immunic Inc (NASDAQIMUX) CEO Dr Daniel Vitt joined Proactive's Stephen Gunnion with news of the publication of extended data from the Phase 2 EMPhASIS trial of vidofludimus calcium in relapsing-remitting multiple sclerosis (RRMS) in the peer-reviewed journal, Neurology® Neuroimmunology & Neuroinflammation, an official journal of the American Academy of Neurology.
Immunic Inc (NASDAQIMUX) Chief Medical Officer Dr Andreas Muehler discusses the complexities of multiple sclerosis (MS) during an interview with Proactive's Stephen Gunnion to mark MS Awareness Month, highlighting the disease's impact, development, and the unmet medical needs of patients.
The Dow Jones index closed lower by over 20 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Immunic, Inc. (NASDAQIMUX) shares are roughly flat following strength early Friday after the company announced a three-tranche private placement of up to $240 million.
Immunic Inc (NASDAQIMUX) Chief Scientific Officer Hella Kohlhof speaks to Thomas Warner at the Proactive London after returning from MSMilan2023, the 9th Joint ECTRIMS-ACTRIMS meeting. She shares some of the main talking points from the event, noting keen interest in forms of multiple sclerosis (MS) not characterised by relapses and saying that for Immunic, the most important was the focus on biomarkers.
